Maintain pressure on reforms to protect NHSNICE rejects stomach cancer drug
NICE has ruled against the use of trastuzumab (Herceptin) to treat stomach cancer, because of uncertainty over how long the drug can extend life.
In draft guidance NICE said that although trials do show that trastuzumab can extend life for some patients with gastric cancer, the data is not clear how long this extension will be. The guidance is out for public consultation until 27 July.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.